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The Util ity of Acute-Phase Proteins in the Assessment of Treatment
Response in Dogs With Bacterial Pneumonia
S.J. Viitanen, A.K. Lappalainen, M.B. Christensen, S. Sankari, and M.M. Rajam€aki
Background: Acute-phase proteins (APPs) are sensitive markers of inﬂammation, and serum C-reactive protein (CRP)
recently has been shown to be a useful diagnostic marker in dogs with bacterial pneumonia (BP). In humans with commu-
nity-acquired pneumonia, APPs also have great utility as follow-up markers aiding in the assessment of treatment response.
Objectives: The aim of our study was to investigate the applicability of APPs as markers of treatment response in dogs
with BP.
Animals: Nineteen dogs diagnosed with BP and 64 healthy dogs.
Methods: The study was conducted as a prospective longitudinal observational study. Serum CRP, serum amyloid A
(SAA), and haptoglobin concentrations were followed during a natural course of BP. Normalization of serum CRP was used
to guide the duration of antibiotic treatment (treatment was stopped 5–7 days after CRP normalized) in 8 of 17 dogs surviv-
ing to discharge; 9 of 17 dogs were treated according to conventional recommendations.
Results: All measured APPs initially were signiﬁcantly increased, but the magnitude of increase was not correlated to dis-
ease severity. C-reactive protein and SAA concentrations decreased rapidly after initiation of antimicrobial treatment. When
normalization of serum CRP was used to guide the duration of antibiotic treatment, treatment duration was signiﬁcantly
(P = .015) decreased without increasing the number of relapses.
Conclusions and Clinical Importance: Serum CRP and SAA reﬂected the recovery process well and therefore may be used
as markers of treatment response. According to the results, the normalization of serum CRP may be used to guide the dura-
tion of antibiotic treatment in dogs with BP.
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Bacterial pneumonia (BP) is an acquired inﬂamma-tion of the lower airways and lung parenchyma sec-
ondary to bacterial infection.1 The clinical
characteristics and microbiological ﬁndings in dogs with
BP have been well described.2–5 However, information
concerning the normalization of clinical and radio-
graphic ﬁndings during the recovery process and guide-
lines on assessing the optimal duration of antibiotic
treatment in BP still are limited.1,6,7
Acute-phase proteins (APPs) are a group of blood
proteins, mainly produced by the liver, which are part
of the innate host defense system.8 The APPs are
involved in the protection against infection as well as in
the regulation of the immune response and inﬂamma-
tion, especially in the early phases of injury.9 The major
positive APPs in dogs, C-reactive protein (CRP) and
serum amyloid A (SAA), have low serum concentra-
tions in healthy dogs. Serum concentrations of CRP
and SAA increase markedly within the ﬁrst hours after
inﬂammatory stimuli and normalize quickly during the
recovery period.9 The APPs have certain advantages in
disease monitoring compared to the CBC. The numbers
of blood leukocytes are largely aﬀected by extravasation
into the pulmonary parenchyma during acute BP,
whereas APPs increase consistently with increasing
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inﬂammatory stimuli.9 Minor and moderate positive
APPs, such as haptoglobin (Hp), show a more gradual
increase and decrease during the acute-phase response
(APR).8 The production of other plasma proteins, so-
called negative APPs (such as albumin and transferrin),
decreases during the APR.8
Being nonspeciﬁc biomarkers of inﬂammation,
increased serum concentrations of CRP, SAA, and Hp
have been observed in dogs with a variety of infectious,
immune-mediated and neoplastic diseases.10–17 Despite
the nonspeciﬁc nature of APPs, serum CRP can be use-
ful in discriminating disease processes such as BP from
other pulmonary diseases.18
The APPs have been shown to decrease after initia-
tion of successful treatment.16,19–21 Additionally, the
increase in serum CRP during long-term follow-up in
dogs with leishmaniasis and immune-mediated pol-
yarthritis predicts the relapse of clinical disease.14,21
The utilization of CRP and SAA as possible prognos-
tic biomarkers also has been studied in dogs, and most
studies concluded that serum CRP or SAA concentra-
tions at presentation could not predict clinical
outcome.22–26 However, persistent increases in serum
CRP after 48–72 hours of treatment were correlated
with poor outcome.22–24 Serum CRP has been widely
studied in humans with community-acquired pneumonia
(CAP), and its use as a diagnostic and follow-up bio-
marker is recommended by current treatment guide-
lines.27,28
Bacterial pneumonia currently is treated with mark-
edly longer antimicrobial courses than is CAP, and
eﬀective means to estimate optimal treatment duration
are lacking.1,6,7,29 Biomarker-guided antimicrobial
treatment has been studied in humans with CAP by
procalcitonin (PCT), a novel inﬂammatory biomarker,
which indicated that PCT-guided antibiotic use
decreased the duration of antimicrobial treatment with-
out increasing the incidence of complications.30–32 Simi-
lar studies assessing CRP-guided antimicrobial use
in humans with CAP are lacking, but serum CRP
has been shown to be useful in decreasing the duration
of antimicrobial treatment in humans with neona-
tal septicemia without increasing the incidence of
complications.33,34
The aim of our study was to describe the changes in
clinical variables, thoracic radiographs, and APPs during
a natural course of BP in dogs as well as comparing these
variables between dogs with less severe BP requiring
<2 days of hospitalization (lsBP) and more severe BP
requiring >2 days of hospitalization (msBP). Addition-
ally, the purpose of our study was to provide information
concerning the application of APPs in the assessment of
treatment response and to investigate whether serum
CRP measurements can aid in the estimation of antimi-
crobial treatment duration in dogs with BP.
Materials and Methods
Study Design
This study was conducted as a prospective longitudinal observa-
tional study.
Study Population
Privately owned dogs diagnosed with BP between March 2011
and December 2012 at the Veterinary Teaching Hospital of the
University of Helsinki were eligible for inclusion in the study.
Dogs with known or suspected concurrent infectious, inﬂamma-
tory or neoplastic diseases capable of increasing APP concentra-
tions were excluded from the study. Dogs with known excess
endogenous glucocorticoids or glucocorticoid medication <4 weeks
before BP were excluded from the Hp measurements.35,36 Pregnant
or lactating bitches and puppies <3 months of age also were
excluded.37 Privately owned blood donor dogs were recruited as
healthy controls for the APP measurements. These dogs had no
signs of illness and had a normal physical examination ﬁndings as
well as normal hematology and biochemistry ﬁndings.
Diagnostic Testing, Sample Collection, and Follow-Up
A full clinical examination was performed, and thoracic radio-
graphs as well as blood, fecal, and respiratory samples were
obtained at presentation as previously described.18 Thoracic radio-
graphs were assessed by the same radiologist (AKL), who was
blinded to the patient data. Bacterial pneumonia was diagnosed
when typical acute signs (at least 3 of the following: fever,
lethargy, dyspnea, tachypnea, cough) were observed and thoracic
radiograph ﬁndings were compatible with BP (ie, an alveolar pat-
tern or a moderate or severe bronchointerstitial or interstitial
pattern).2,3,6 A bacterial origin was demonstrated by respiratory
cytology or bacterial culture as previously described.18 A post-
mortem examination was performed on dogs that died or were
euthanized during hospitalization, to conﬁrm the diagnosis of BP.
After initial examination, dogs were examined daily during hos-
pitalization (clinical examination and individually chosen methods
including blood tests, thoracic imaging, or both) and at follow-up
visits at 7- to 10-day intervals after discharge. The last follow-up
visit was scheduled 2 weeks after antimicrobial treatment had con-
cluded. A clinical examination was performed during the follow-
up visits, and blood samples for hematology, APP measurements,
and arterial blood gas analysis were obtained and thoracic radio-
graphs were repeated. Owners were contacted 4–8 weeks after the
last follow-up visit to obtain information on possible relapses.
Initially, antimicrobial treatment was chosen empirically to
cover the most common causative organisms in BP. Later, when
bacterial culture and antimicrobial susceptibility results were avail-
able, the treatment regimen was re-evaluated, and if necessary,
changes were made according to the culture results. During hospi-
talization, antimicrobials were administrated IV, and PO treatment
was continued after discharge. Dogs were discharged when they
did not require oxygen supplementation and were capable of main-
taining normal hydration and nutrition PO. At the beginning of
the trial, the duration of antimicrobial treatment followed conven-
tional recommendations, and dogs were treated for 3–6 weeks or
1–2 weeks beyond the resolution of alveolar density on the tho-
racic radiographs.1,6 Antimicrobial treatment of dogs entering our
study during 2012 was discontinued 5–7 days after serum CRP
returned to normal (<25 mg/L). Antibiotic treatment was discon-
tinued by the CRP-guided approach only when owners consented.
Sample Handling and Analysis
Hematology, serum biochemistry, arterial blood gas analysis,
blood cultures, and fecal analysis along with cytological and
microbiological analysis of respiratory samples were performed as
previously described.18 Coagulation parameters prothrombin time
(PT) and activated partial thromboplastin time (aPTT) were evalu-
ated with commercial test kits for dogs,a,b. Serum samples
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obtained for APP analysis either were immediately analyzed or
stored at 80° C until analyzed.38–40 CRP was analyzed by mag-
netic permeability-based immunoassayc validated for dogs.41 C-
reactive protein values below the detection limit for the CRP assay
(<10 mg/L) were set at 5 mg/L. Results above the upper detection
limit for the assay (>210 mg/L) were set at 211 mg/L. A CRP
ratio (CRP concentrations at 24, 48, and 72 hour divided by the
initial concentration), describing the decrease in CRP during early
recovery, was calculated after initiation of treatment in dogs with
samples available for the time point in question. Samples for SAA
analysis were sent on dry ice to an external laboratoryd and mea-
sured by an automatede latex agglutination testf validated for
dogs.42 Haptoglobin was measured by a commercial colorimetric
methodg validated for dogs.43
Statistical Analyses
Normality testing was performed by Shapiro–Wilk’s test of nor-
mality and normal Q–Q plots. The diﬀerences between dogs with
lsBP and msBP as well as between dogs with Escherichia coli-
induced BP and BP caused by other organisms were evaluated by
the independent samples Student’s t-test (normally distributed vari-
ables) and Mann–Whitney U-test (non-normally distributed vari-
ables). The Mann–Whitney U-test also was used to evaluate
whether there were diﬀerences in bronchoalveolar lavage ﬂuid
(BALF) and transtracheal wash (TTW) ﬂuid diﬀerential cell
counts and whether the duration of antimicrobial treatment dif-
fered in dogs with CRP-guided and conventional treatment. Initial
serum CRP, SAA, Hp, and albumin concentrations were com-
pared among groups of healthy dogs as well as dogs with <2 days
and >2 days of hospitalization by the Mann–Whitney U-test. Bon-
ferroni correction was used in the pairwise comparisons to control
for the family-wise error rate.
The correlation between serum APPs and clinical variables (body
temperature, respiratory rate, partial pressures of arterial oxygen
[PaO2] and carbon dioxide [PaCO2], alveolar–arterial gradient
[A-aO2], blood leukocyte parameters, and BALF cytology as well as
duration of clinical signs and duration of hospitalization) was
assessed with Spearman’s correlation coeﬃcients. P-values < .05
were considered statistically signiﬁcant.
The mean curves (Fig 2A–D) were calculated with random-
eﬀects analysis of variance regression models (ANOVA). For CRP
and SAA, a logarithmic transformation was computed to normal-
ize the distribution and the ﬁtted values estimated from the models
were transformed back to original scale to represent the geometric
mean of the response in time. For Hp and PaO2, the absolute val-
ues were used as the response, and the mean curves computed
directly from the ﬁtted values. As explanatory variables, the mod-
els included the ﬁxed eﬀects of group, day and the 2-way interac-
tion of group 9 day, and random eﬀects of dog and dog 9 day.
All statistical analyses were performed by commercial statistical
softwareh,i,j.
Ethical Approval and Owner Consent
This study was approved by the ethics committee of the Univer-
sity of Helsinki. Owner consent was obtained from owners of the
dogs before participation.
Results
Dogs
Nineteen dogs diagnosed with BP were included, and
64 privately owned healthy blood donor dogs were cho-
sen as controls for the APP measurements. Age, body
weight, and sex distribution of dogs participating in our
study are presented in Table 1. The dogs represented
various breeds without overrepresentation of any single
breed.
All dogs were presented as acute emergency cases of
varying severity. Fifteen of 19 dogs required hospitaliza-
tion. One dog died as a consequence of severe BP
despite the fact that the bacteria isolated were suscepti-
ble to the antibiotics used. One dog was euthanized as a
consequence of refractory BP caused by a multiresistant
E. coli. None of the owners refused hospitalization or
selected euthanasia for ﬁnancial reasons.
Concurrent disease processes possibly predisposing to
the development of BP were identiﬁed in 6 of 19 dogs
(parainﬂuenza or respiratory corona virus infection [5/6],44
advanced chronic bronchitis [1/6]).
Table 1. Microbiological ﬁndings of respiratory samples (bronchoalveolar lavage ﬂuid n = 11, transtracheal wash
ﬂuid n = 5, transthoracic ﬁne-needle aspiration n = 2, and fresh sputum sample n = 1) and blood cultures in dogs
with bacterial pneumonia (n = 19).
Dogs with Signiﬁcant Bacterial
Growth in Primary Culture (n = 12)
Dogs with Bacterial Growth
After Enrichment (n = 5)
Dogs with No Bacterial
Growth (n = 2)
Antimicrobial treatment before sampling 6/12 4/5 1/2
Culture results Escherichia coli 3/12
Pasteurella sp. 2/12
Streptococcus sp. 2/12
Haemophilus sp. 1/12
Mycoplasma sp. 1/12
Actinomyces sp. 1/12
Nocardiopsis sp. 1/12
E. coli and Arcanobacter sp. 1/12
Actinomyces sp. 2/5
Streptococcus sp. 1/5
Pasteurella sp. 1/5
Haemophilus sp. 1/5
Intracellular bacteria in cytology
or Gram stain
7/12 1/5 0/2
Blood culture performed 5/12 4/5 1/2
Positive blood culture 2/5 1/4 0/1
Blood culture results E. coli 2/2 Staphylococcus sp. 1/1
Blood culture consistent with
respiratory culture
2/2 0/1
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Clinical Findings
Clinical data as well as duration of clinical signs and
hospitalization are presented in Table 1. Fecal analyses
were available for 15 of 19 dogs, and each sample was
negative for lungworms and intestinal parasites.
Prothrombin time and aPTT were measured in 8 of 19
dogs on 15 diﬀerent occasions either at presentation or
during hospitalization. Prothrombin time was normal in
all measurements. Mildly prolonged aPTT was noted in
3 of 8 dogs. In all 3 dogs, E. coli was detected in respi-
ratory samples. One of these dogs was hospitalized for
5 days; 2 did not survive to hospital discharge.
Acute-Phase Proteins Measurements
Serum CRP, SAA, and Hp concentrations are pre-
sented in Figure 1A–C. In 3 dogs, initial serum CRP
concentrations exceeded the upper detection limit for
the assay (>210 mg/L) were set at 211 mg/L. Three
dogs had received exogenous glucocorticoids (a single
PO dose of prednisolone or hydrocortisone [2/3] and
daily inhaled ﬂuticasone [1/3]) before inclusion and 1
dog was diagnosed with Cushing’s disease after the
study period. Serum CRP and SAA (r = 0.60,
P = .015), CRP and Hp (r = 0.61, P = .010) as well as
SAA and Hp (r = 0.85, P < .001) at presentation were
signiﬁcantly positively correlated. Serum amyloid A
concentration was signiﬁcantly negatively correlated
with serum albumin concentration (r = 0.53,
P = .035), but CRP (r = 0.22, P = .40) and Hp
(r = 0.15, P = .58) were not. Serum APPs at presenta-
tion were not signiﬁcantly correlated with variables of
disease severity, such as duration of hospitalization
(CRP: r = 0.36, P = .24; SAA: r = 0.462, P = .072; Hp:
r = 0.305, P = .235), arterial PaO2 (CRP: r = 0.353,
P = .138; SAA: r = 0.450, P = .080; Hp: r = 0.48,
P = .052), or A-aO2 (CRP: r = 0.35, P = .14; SAA:
r = 0.42, P = .11; Hp: r = 0.42, P = .090).
Changes in serum CRP, SAA, Hp, and in arterial
PaO2 during the follow-up period are presented in
Figure 2A–D.
The CRP ratio was calculated for hospitalized
patients at 24 hours (median, 1.0; interquartile range
[IQR], 0.6–2.2; n = 11), 48 hours (median, 0.95; IQR,
0.8–1.1; n = 8), and 72 hours (median, 1.0; IQR, 0.8–
1.2; n = 5). C-reactive protein concentration continued
to increase in the ﬁrst 24 hours in 5 of 11 dogs. The
CRP ratios after 24 hours (r = 0.35, P = .30), 48 hours
(r = 0.46, P = .25), and 72 hours (r = 0.15, P = .81)
were not correlated with the duration of hospitalization.
Radiographic Findings
An alveolar lung pattern was detected in 15 of 19
dogs, involving a single lobe in 5 of 15 dogs and multi-
ple lobes in 9 of 15 dogs. A patchy alveolar pattern
involving several lobes was found in 1 dog. The cranial
(12/15) and middle (7/15) lobes most often were
aﬀected. A moderate-to-severe interstitial or bronchoin-
terstitial lung pattern was identiﬁed in 4 of 19 dogs at
presentation. An alveolar pattern in multiple lobes at
presentation was detected in 4 of 10 dogs with lsBP and
in 6 of 9 dogs with msBP.
The alveolar pattern found in 13 of 17 dogs was
resolved in a median of 10 days (IQR, 8–15 days), and
9 of 13 dogs had cleared alveolar inﬁltrates by day 10.
At a follow-up visit 2 weeks after discontinuation of
antibiotics, 15 of 17 dogs still had a mild-to-moderate
bronchial, bronchointerstitial, or interstitial patterns on
thoracic radiographs.
Respiratory Samples
Bronchoalveolar lavage ﬂuid was retrieved in 11 of
19, and TTW was performed in 5 of 19. When BAL or
TTW were not available (mainly due to the small size
of the patient or the severity of BP), a transthoracic
aspirate (TTA) was collected in 2 of 19 and a fresh spu-
tum sample in 1 of 19 dogs. Microbiological analysis
was performed in all dogs and the results are presented
in Table 1. A cytological analysis was performed in 18
of 19 dogs (cytology was not performed in 1 TTW sam-
ple). Results from the cytology analyses are presented
in Table 2. Because BALF and TTW ﬂuid cytology did
not diﬀer signiﬁcantly in other cell percentages apart
from the percentage of epithelial cells (median in
BALF, 0.0; IQR, 0.0–0.0 versus median in TTW ﬂuid,
7.1; IQR, 0.2–16.1; P = .026), combined results are pre-
sented for the 2 sampling techniques. Cytology in TTA
(n = 2) and fresh sputum (n = 1) samples consisted of
markedly increased numbers of neutrophils and intra-
cellular bacteria, and an abundant bacterial growth was
detected in these samples. The diagnosis of BP was
additionally conﬁrmed by postmortem examination in
1 dog with sputum sampling and in 1 dog with TTA
sampling.
Dogs with E. coli as a causative agent required signif-
icantly (P = .049) longer hospitalization (median,
4.5 days; range, 3.5–5.5) compared to dogs with other
causative bacteria (median, 1.0 days; range, 0.5–14.0)
and 2 of 4 dogs with E. coli-induced BP died or were
euthanized because of disease severity.
Duration of Antimicrobial Treatment
Of the 17 dogs surviving to discharge, 9 received
antibiotics according to conventional recommendations
(median duration of treatment, 35 days; IQR, 29–
48 days) and CRP was not used for determining the
duration of the treatment. Less severe BP and msBP
were observed in 6 of 9 and 3 of 9 of these dogs, respec-
tively. Antimicrobial treatment was discontinued 5–7
days after CRP normalization in 8 of 17 dogs (median
duration of treatment, 21 days; IQR, 19–29 days). Less
severe BP and msBP were observed in 4 of 8 and 4 of 8
of these dogs, respectively. Treatment guided by CRP
(median, 21 days) was signiﬁcantly shorter (P = .015)
than conventional treatment (median, 35 days). Sixteen
of 17 dogs did not have clinical signs or ﬁndings sugges-
tive of BP relapse at follow-up visits 2 weeks after
antibiotic discontinuation or during follow-up phone
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calls 4–8 weeks after the follow-up visit. One dog trea-
ted conventionally had a relapse of BP after antibiotic
discontinuation, and Cushing’s disease was later found
as a predisposing factor. Bacteria susceptible to the ini-
tially chosen antimicrobials were detected in 15 of 17
dogs. In 2 dogs, bacterial growth was not detected and
therefore antimicrobial susceptibility could not be
addressed. Of these 2 dogs, 1 was treated according to
conventional recommendations and 1 was treated by
CRP guidance.
Discussion
All measured positive APPs were signiﬁcantly
increased in dogs with BP at presentation compared to
healthy controls. This ﬁnding is in agreement with pre-
vious reports describing CRP and SAA in dogs with
BP.10,18,45 Haptoglobin concentrations have not been
reported previously, but because signiﬁcant increases in
serum Hp have been reported 24 hours after an inﬂam-
matory stimulus, increased concentrations also were
expected in BP.9 However, it must be emphasized that
APPs are highly nonspeciﬁc inﬂammatory markers and,
in addition to BP, increased concentrations may be
encountered in a variety of disease processes.8,9
As expected, all positive APPs (CRP, SAA, Hp) cor-
related positively with each other. However, a negative
correlation with albumin did not occur in all compar-
isons. This is most likely due to the long half-life of
albumin, resulting in a late response not noticeable in
acute BP.9
Serum APP concentrations at presentation did not
diﬀer signiﬁcantly in dogs with lsBP and msBP. Addi-
tionally, serum CRP, SAA, or Hp at presentation did
not correlate signiﬁcantly with markers of disease sever-
ity, such as arterial PaO2 and the duration of hospital-
ization. Initial serum CRP, SAA, or Hp concentrations
in dogs with BP therefore may not be useful indicators
of disease severity. A similar observation has been made
in studies describing CRP in human patients with
CAP.46,47
C-reactive protein and SAA rapidly decreased after
initiation of treatment (Fig 2A,B). These ﬁndings indi-
cate that CRP and SAA are useful markers of treat-
ment response. Haptoglobin showed a more gradual
increase and decrease and therefore did not reﬂect clini-
cal recovery as well as CRP and SAA. Because there is
a wider range of concentrations and the magnitude of
change is more pronounced in SAA compared to CRP,
SAA might be a better diagnostic and follow-up marker
than CRP in dogs with BP, as already suggested by a
recent study comparing CRP and SAA as diagnostic
markers of systemic inﬂammation.45
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Fig 1. (A–C) Box and whisker plots showing serum acute-phase
protein concentrations in healthy dogs (HD), in dogs with less sev-
ere bacterial pneumonia (BP) requiring <2 days of hospitalization
(lsBP) and in dogs with more severe BP requiring >2 days of hos-
pitalization (msBP). (A) C-reactive protein (CRP, mg/L) in HD
(median 11.0, interquartile range [IQR] 5.0–16.0, n = 47), in lsBP
(101.5, 62.3–182.5, n = 10), and in msBP (142.0, 98.0–211.0,
n = 9). (B) Serum amyloid A (SAA, mg/L) in HD (median 3.9,
IQR 1.7–9.1, n = 64), in lsBP (1,048.2, 236.3–1,522.2 n = 9), and
in msBP (1,336.9, 778.3–3,650.0, n = 7). (C) Haptoglobin (Hp,
mg/mL) in HD (median 0.5, IQR 0.2–1.7, n = 64), in lsBP (3.7,
2.5–7.3, n = 8), and in msBP (6.9, 2.7–13.3, n = 6).
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C-reactive protein continued to increase within the
ﬁrst 24 hours in 5 dogs. This is not unexpected because
dogs with BP were presented acutely and CRP is known
to reach peak concentrations approximately 24 hours
after the onset of an inﬂammatory stimulus.48 Conse-
quently, it is not meaningful to interpret the possible
CRP decrease as early as 24 hours after initiation of
treatment. However, a decrease in serum CRP is
expected 48–72 hours after initiation of successful treat-
ment, and a failure to show a decrease has been associ-
ated with a poor prognosis in dogs with systemic
inﬂammatory conditions.22–24 Consecutive measure-
ments of CRP have been to be found useful in humans
with CAP, and the magnitude of CRP decrease at days
3 and 4 has been shown to have prognostic value.49–51 A
connection also has been shown between the pattern of
serum CRP concentrations and outcome in humans.
Patients with persistently high CRP (so-called nonre-
sponse) or an increase in serum CRP after an initial
decrease (so-called biphasic response) during the ﬁrst
days of hospitalization had a poor prognosis.52 In our
study, the CRP ratio, describing the magnitude of
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Fig 2. (A–D) Geometric mean curves for serum C-reactive protein (CRP) and serum amyloid A (SAA) concentrations as well as mean
curves for serum haptoglobin (Hp) concentrations and partial pressure of arterial oxygen (PaO2) values over time during a natural course
of bacterial pneumonia (BP). A solid line represents dogs with less severe disease (requiring <2 days of hospitalization; CRP, SAA and
PaO2 n = 10, Hp n = 9), and a dashed line represents dogs with more severe BP (requiring >2 days of hospitalization; CRP and PaO2
n = 9, SAA n = 7, Hp n = 6, including 2 mortalities). Individual measurements are marked with a circle (o) for dogs with a less severe dis-
ease and with a plus sign (+) for dogs with a more severe disease.
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decrease after 48 or 72 hours, did not correlate with the
duration of hospitalization. This ﬁnding could be a con-
sequence of the small number of samples available for
CRP measurement at 72 hours: Only 5 dogs with msBP
were still alive and hospitalized 72 hours after presenta-
tion. Another limitation concerns the method used for
CRP measurements. The upper detection limit for the
assay used was 210 mg/L, and measurements exceeding
this concentration were set at 211 mg/L. Doing so
underestimated the increase in serum CRP, because it
has been shown that serum CRP can increase markedly
above 211 mg/L in dogs with aspiration pneumonia.45
This approach will aﬀect the interpretation of the CRP
ratio during the recovery process. These limitations
make the interpretation of the CRP ratio in our study
less informative. One dog, which was euthanized because
of refractory BP, had a biphasic CRP response pattern
similar to that described in connection with poor prog-
nosis in humans with CAP.52
Regarding other variables, dogs with msBP were char-
acterized by a more pronounced left shift and lymphope-
nia and were signiﬁcantly more hypoxemic. Respiratory
samples in dogs with msBP were characterized by signiﬁ-
cantly more pronounced neutrophilia, eosinopenia, and
lymphopenia compared to dogs with lsBP. These vari-
ables therefore could be useful as early markers aiding in
the identiﬁcation of dogs with a more severe course of
BP. Escherichia coli as a causative agent additionally was
correlated with a more severe course of BP. Moreover,
coagulation abnormalities were detected only in dogs
with msBP caused by E. coli. These ﬁndings likely are
due to endotoxin produced by E. coli, aﬀecting hemody-
namics, blood clotting, and cellular and humoral
immunity.53 A similar ﬁnding of increased disease sever-
ity has been described in E. coli-induced CAP.54 Addi-
tionally, prolonged aPTT has been correlated with a
worse prognosis in both humans and dogs with systemic
inﬂammation or sepsis.55,56
Initial radiographic ﬁndings were consistent with pre-
viously reported ﬁndings in dogs with BP.2,3 The resolu-
tion of the alveolar lung pattern was followed during
hospitalization and follow-up visits. However, because
thoracic radiographs were not repeated daily, an exact
time point for the resolution could not be determined.
Alveolar inﬁltrates resolved relatively rapidly in our
study (69% of dogs had cleared alveolar inﬁltrates by
day 10) compared to studies of humans. Only 33% of
human patients with CAP had clearance of radiographic
Table 2. Comparison of demographic, clinical, and respiratory cytology ﬁndings at presentation in dogs with less
severe bacterial pneumonia (BP) (requiring <2 days of hospitalization, n = 10) and more severe BP (requiring
>2 days of hospitalization, n = 9, including 2 mortalities).
Dogs with <2 Days of Hospitalization
Mean  SD or Median (IQR)
Dogs with >2 Days Hospitalization
Mean  SD or Median (IQR) P-Value
Duration of hospitalization (days) 1.0 (0.5–1.1) 5.5 (3.3–5.8)
Age (years) 1.5 (0.8–5.6) 5.8 (2.6–7.6) .211
Sex Male 6/10
Female 4/10
Male 5/9
Female 4/9
Duration of clinical signs (days) 3.0 (1.0–7.0) 1.5 (1.0–3.5) .315
Body weight (kg) 36.5  17.5 33.6  24.6 .764
Body temperature (°C) 39.3  0.9 39.6  0.9 .419
Respiratory rate (breaths/min) 43  22 61  17 .064
Blood hematology (n = 19)
Leukocyte count (109/L) 20.2  16.3 12.1  6.5 .183
Segmented neutrophil count (109/L) 15.9  14.2 9.3  5.5 .234
Band neutrophil count (109/L) 0.1 (0.0–0.7) 1.4 (0.3–2.8) .035
Lymphocyte count (109/L) 2.2  1.6 0.5  0.3 .009
Eosinophil count (109/L) 0.4  0.4 0.1  0.2 .078
Monocyte count (109/L) 0.7 (0.4–2.3) 0.4 (0.2–1.4) .278
Basophil count (109/L) 0.0 (0.0–0.0) 0.0 (0.0–0.0) .720
Arterial blood gas analysis (n = 19)
Arterial PaO2 (mmHg) 84.6  6.8 69.0  9.8 .001
Arterial PaCO2 (mmHg) 30.8 (27.0–31.1) 28.8 (28.4–32.2) .842
Alveolar–arterial O2 gradient 30.8  10.8 46.5  9.2 .003
pH 7.41  0.02 7.41  0.6 .893
HCO3 (mmol/L) 18.2  1.7 18.7  3.4 .669
Base excess (mEq/L) 4.6  1.3 4.3  3.9 .833
Respiratory sample cytology (n = 15)
Neutrophils (%) 14.7 (5.3–76.2) 96.4 (46.8–97.8) .019
Eosinophils (%) 3.7 (0.6–13.2) 0.0 (0.0–0.4) .008
Mast cells (%) 0.0 (0.0–2.7) 0.0 (0.0–0.0) .254
Lymphocytes (%) 14.6  11.2 2.3  3.1 .008
Macrophages (%) 42.9  22.9 17.2  27.6 .077
Epithelial cells (%) 0.0 (0.0–0.2) 0.0 (0.0–8.5) 1.000
SD, standard deviation; IQR, interquartile range.
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inﬁltrates at day 7 and 62% at day 28, and it also has
been shown that radiographic normalization lags behind
clinical cure as assessed by physicians.57,58 With CAP,
current research has not been able to show beneﬁts for
routinely repeating thoracic radiographs after clinical
recovery.57–59 Repeating thoracic radiographs during
and after hospitalization therefore is not recommended
in patients with uncomplicated recovery.27 Additional
information gained by thoracic radiographs, especially
after the clearance of alveolar inﬁltrates, was minimal in
our study in dogs with otherwise satisfactory clinical
recovery.
Antimicrobial treatment currently is recommended
for 3–6 weeks or 1–2 weeks beyond the resolution of
radiographic changes.1,6,7 Markedly shorter antimicro-
bial courses are used in CAP. Antibiotics are recom-
mended for 7–10 days in cases of mild-to-moderate
CAP, and the use of biomarkers has proved useful in
determining optimal treatment duration.27,29–31,33,34,60
No published clinical studies exist addressing the opti-
mal duration of antimicrobials in dogs with BP, and
current recommendations may overestimate the treat-
ment duration needed, especially in uncomplicated
cases. Considering the variety of infectious agents and
the individual diﬀerences in the interactions between
microbe and the host immune system, a need also exists
in dogs with BP for customizing antibiotic treatment
duration according to disease severity and response
rate. In our study, normalization of CRP was used to
guide duration of antimicrobial treatment in 8 of 17
dogs and resulted in signiﬁcantly decreased treatment
duration compared to 9 of 17 conventionally treated
dogs. It would have been ideal to randomize the chosen
treatment regimen and stratify the randomization
according to disease severity. Instead, conventional
treatment was used at the beginning of the study,
because previous information on the applicability of
CRP to predict treatment duration was lacking. When
clinical experience was gained and serum CRP was
found to reﬂect the recovery process well, it was consid-
ered safe to stop administering antibiotics after CRP
normalization. Ending antimicrobials at the point of
CRP normalization was still considered premature and,
to increase safety, antimicrobials were administered for
5–7 days after CRP normalization. Relapses of BP were
not noted in dogs receiving a CRP-guided course of
antibiotics, and therefore, the approach appears to be
safe. However, because the incidence of relapse was low
in both groups, our study was not able to identify an
optimal end point for antimicrobial treatment and even
shorter courses than those used in the CRP-guided
group may have been suﬃcient in dogs with BP. Addi-
tionally, the small number of dogs and lack of random-
ization are limitations, and larger randomized studies
are warranted.
In conclusion, dogs with BP had signiﬁcantly
increased serum CRP, SAA, and Hp at presentation,
and CRP and SAA decreased rapidly after initiation of
treatment and reﬂected the recovery process well. When
CRP normalization was used to guide the duration of
antibiotic treatment, treatment duration was signiﬁ-
cantly decreased without increasing the number of
relapses.
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